- Medicine Name: Livtencity
- Generic Name: Maribavir
- Dosage Form & Strength: Tablets: 200 mg of Maribavir
- Manufactured By: Takeda Pharmaceuticals, Inc.
Livtencity is a Cytomegalovirus pUL97 kinase inhibitor approved for both adults and pediatric patients (aged 12 years and older and weighing at least 35 kg) to treat post-transplant CMV infection/disease, refractory to treatment (with or without genotypic resistance) with drugs valganciclovir, ganciclovir, cidofovir or foscarnet.
Recommended Dosage: The recommended dosage for both adults and pediatric patients (aged 12 years and more and weighing minimum 35kg) is 400 mg (2 tablets of 200 mg) taken by mouth (orally) twice daily with or without meal/food.
If Livtencity is used in conjunction with drug carbamazepine, increase the dosage of Maribavir to 800 mg twice daily. If Livtencity is used in conjunction with phenytoin or phenobarbital, increase the dosage of Maribavir to 1,200 mg twice daily.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.